Why is Novartis’ Copaxone copy lagging? It’s all about coverage, analyst explains

Carly Helfand Typically, the first generics for blockbuster meds get off to a running start. Not so with Novartis' generic of Teva's multiple sclerosis standout Copaxone, though–and ...

Horizon steps up its official Depomed pursuit with campaign website

Carly Helfand Horizon Pharma has officially begun mailing solicitation materials to shareholders of unwilling M&A target Depomed, including a letter related to its efforts to call ...

Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

Carly Helfand Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers–including Evercore ISI analyst Umer Raffat, who ...

Lilly’s CEO keeps faith in the pipeline as biotech gets ‘too expensive’

Damian Garde Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar. FierceBiotech ...

KemPharm spikes as its anti-abuse pain drug rolls toward the FDA

Damian Garde KemPharm, at work on an abuse-deterrent formulation of hydrocodone, said its lead drug performed well in a study designed to determine how easily the pill can be ground ...

UPDATED: GSK site closed after Legionella bacteria detected in cooling tower

Eric Palmer After detecting the bacteria for Legionnaires' disease in its cooling tower, GlaxoSmithKline has temporarily closed a manufacturing plant in North Carolina and sent ...

RIP: AstraZeneca clips two pipeline programs in Q2

John Carroll Every quarter AstraZeneca notes at the end of its financial report which of its new drug programs are being discarded and dropped from the pipeline. FierceBiotech News

Bristol-Myers’ next-gen HIV med gets FDA ‘breakthrough’ designation

Tracy Staton Bristol-Myers Squibb nabbed a "breakthrough" tag from the FDA for its next-gen HIV therapy aimed at patients who become resistant to the drugs now in use. FiercePharma ...

Viehbacher returns to lead Swiss billionaire’s $2B biotech fund

Alok Saboo FierceBiotech News

Billionaire Soon-Shiong arranges a $71M crossover round for Conkwest

John Carroll Biotech billionaire Patrick Soon-Shiong is pumping $ 71 million into Conkwest as it preps a move to go public in a $ 172.5 million IPO. FierceBiotech News

Bristol-Myers is the next big tenant in biotech’s hottest neighborhood

Damian Garde Bristol-Myers Squibb's latest R&D reshuffle calls for a consolidated presence in Cambridge, MA's booming Kendall Square, and the drugmaker has signed on to ...

Mylan CFO jetting off to Israel for stock exchange meeting: Reuters

Tracy Staton Mylan is sending its CFO, John Sheehan, on the road in Israel. FiercePharma News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS